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tors from a sample of patients (or caregivers of pediatric
patients), physicians specialist in hemophilia care, pharmacists
with experience in storing/delivering coagulation factor concen-
trates. METHODS: A Discrete Choice Experiment was con-
ducted, by describing possible products with 7 attributes selected
from a previous pilot study: “viral safety”, “risk of anamnestic
response”, “possibility of undergoing major surgery”, “fre-
quency of infusions in prophylaxis”, “number of injections to
stop bleeding”, “time to stop bleeding”, “time to pain recovery”.
Cost, expressed as increase of health care taxes, was added to
estimate willingness to pay towards these attributes. The respon-
dents were asked to choose among 16 pair-wise choice sets.
A random-effect logit model was used to analyse the data.
RESULTS: Thirty-seven patients or proxies (their caregivers), 39
physicians, 25 pharmacists were interviewed. All the patients
had severe hemophilia A, historical median (min-max) peak
titre = 164 (5–16,400) BU/mL. Among all the respondents, the
hypothesized direction of preferences was conﬁrmed (e.g. lower
risk of infections was preferred than higher risk) and the impor-
tance of preferences was statistically signiﬁcant: p-values < 0.01
for every attribute. The 3 subgroups anyway reported different
preferences in some attributes. CONCLUSION: this study
revealed patients/caregivers’, physicians’ and pharmacists’ pref-
erences towards the products used to treat hemophilic patients
with inhibitors. Understanding the preferences from different
perspectives can be useful to optimize the beneﬁts deriving
from the decisions on treatments for hemophilic patients with
inhibitors.
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OBJECTIVES: Using a sample of adult Medicaid enrollees, this
study examined physician prescribing practices associated with
MDD. We compared behavioral, physical, and pharmacy service
use and cost outcomes associated with different prescribing pat-
terns. Speciﬁcally, we examined three cohorts of enrollees: 1)
persons with MDD; 2) persons with diabetic peripheral neuropa-
thy (DPN); and 3) persons with MDD and DPN. We compared
outcomes for patients prescribed Duloxetine to those prescribed
other antidepressant medications. METHODS: The sample
included 32,663 patients diagnosed with MDD and or DPN who
were enrolled in the Florida Medicaid Program during FY2003-
05. Three years of claims data were used to compare demograph-
ics, diagnostic characteristics, antidepressant medication use, and
service expenditures six months prior to and one year after the
index prescription event. RESULTS: Among persons diagnosed
with MDD, the majority (84.5%) received SSRIs alone or in
combination with other antidepressants, 29.2% received SNRIs
alone or in combination, and 15.3% received TCAs alone or in
combination. A large majority (86.5%) also received prescription
pain medication. Of these patients, more than half received pre-
scription narcotics on a daily basis. Predictors of increased
service use and cost following initiation of antidepressant treat-
ment included older age, female gender, and pre-index prescrip-
tion costs. Results indicated physical health care costs increased
after any switches in antidepressants. However, behavioral health
costs decreased for all treated patients over time, most dramati-
cally for inpatient service expenditures. Patients receiving Dulox-
etine reduced their narcotic use following treatment, while
patients receiving other antidepressant medications maintained
or increased narcotics use. CONCLUSION: Current data indi-
cates many patients with MDD also experience chronic pain
conditions requiring narcotics or other pain medications. SNRI’s
may facilitate a reduction in pain medication use and therefore
might be the antidepressant of choice for patients with co-morbid
MDD and chronic pain.
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OBJECTIVES: To summarize published data on the burden of
GAD to assist decision makers in Germany. METHODS: A
review of English-language studies on the human, health care and
economic burden of GAD in Germany. Studies were identiﬁed
using electronic databases (MEDLINE/EMBASE) and references
from published articles. RESULTS: National prevalence esti-
mates indicate that GAD affected 1.5% of adults in the general
population in the past 12-months and 5.3% of primary care
patients in the past 1-month. GAD commonly co-occurred with
other mental disorders, especially major depression (MD).
Impairments observed in people with GAD were not merely due
to comorbidity. People with pure GAD (GAD without comorbid
MD) reported high levels of occupational impairment that were
similar or greater in magnitude compared to that of people with
pure MD (MD without comorbid GAD). People with pure GAD
also reported more severe mental and physical health status
impairments compared to people with pure MD. High use of
health care resources among GAD primary care patients was
not solely due to comorbidity. The proportion of comorbid
GAD/MD cases was smaller than that of pure GAD cases
(4-week point prevalence estimates of 1.6% and 3.8%, respec-
tively). A greater proportion of primary care patients with
comorbid GAD/MD (43%) and pure GAD (42%) reported high
use of specialists (2 + visits/year) than pure MD patients (36%).
A greater proportion of GAD patients sought help for somatic
illness/complaints (48%), pain (35%) and sleep problems (33%)
than for anxiety (13%). GAD was considerably less likely to be
recognized and treated than MD. The per-patient cost of GAD
(€1628 in 2004) was higher than that of any other anxiety
disorder, owing to lost work and health care utilization. CON-
CLUSION: German data show that GAD is a distinct and bur-
densome disorder. Improved recognition and treatment of GAD
should be an important public health priority.
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OBJECTIVES: To present the outcomes associated with olanza-
pine treatment of schizophrenia patients participating in the
Olanzapine Post Marketing Surveillance in Japan (OPMS-J), and
to compare the maintenance rate of olanzapine in the OPMS-J
with that of typical and atypical antipsychotic medication in
the Schizophrenia Outpatient Health Outcomes (SOHO) study.
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